Form 4: Verastem CFO Daniel Calkins Receives RSU Grant

Verastem, Inc. Chief Financial Officer Daniel Calkins was granted 16,665 restricted stock units, aligning his interests with shareholders.

Summary

• Daniel Calkins, Chief Financial Officer of Verastem, Inc. (VSTM), was granted 16,665 restricted stock units (RSUs).
• The transaction date for this acquisition was January 21, 2026.
• Each RSU represents the contingent right to receive one share of Common Stock.
• The RSUs will vest in three equal annual installments of 33.3% on the first three anniversaries of January 21, 2026.
• The award will be fully vested on January 21, 2029, provided Calkins continues to serve as an employee or service provider.
• Following this transaction, Daniel Calkins beneficially owns 121,384 shares of Common Stock directly.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive is generally a positive signal as it aligns management's interests with shareholders and promotes retention. It is a standard compensation practice and not indicative of any immediate operational or financial changes, hence a moderately positive score.

Positives

• The grant of restricted stock units aligns the Chief Financial Officer's long-term interests with those of the company's shareholders.
• The vesting schedule encourages retention of key management personnel over a three-year period.

Negatives

• The RSUs do not have an immediate cash value and are subject to a vesting schedule, meaning the shares are not immediately available to the recipient.

Future Outlook

The vesting schedule for the restricted stock units indicates a commitment to retaining the Chief Financial Officer for at least the next three years, tying a portion of his compensation to the company's future performance and stock value.

Industry Context

The grant of restricted stock units is a standard practice in executive compensation across various industries, particularly in biotechnology and pharmaceuticals, to attract, retain, and incentivize key management by aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• The use of restricted stock units with a multi-year vesting schedule is a common and widely accepted form of long-term incentive compensation for executives in publicly traded companies, consistent with practices observed in peer companies within the biotechnology sector.
• The grant size of 16,665 RSUs for a Chief Financial Officer is within typical ranges for companies of similar market capitalization and stage of development, aiming to provide meaningful equity participation without excessive dilution.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's financial incentives with long-term shareholder value creation, potentially leading to more focused management decisions aimed at increasing stock price.
• Employees: The compensation structure for a key executive may set a precedent or reflect the company's overall approach to long-term incentives for its workforce.

Next Steps

• The RSUs will vest in annual installments on January 21, 2027, January 21, 2028, and January 21, 2029, contingent on continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) and does not contain new information that would fundamentally alter the investment thesis for Verastem, Inc. While positive for management alignment, it does not provide a basis for a change in investment recommendation.

Keywords

Verastem, VSTM, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Daniel Calkins, Stock Grant